{
    "id": 4921,
    "fullName": "MYC over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MYC over exp indicates over expression of the Myc protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4609,
        "geneSymbol": "MYC",
        "terms": [
            "MYC",
            "bHLHe39",
            "c-Myc",
            "MRTL",
            "MYCC"
        ]
    },
    "variant": "over exp",
    "createDate": "04/16/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of lung cancer cells harboring increased Myc activity in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9902,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) decreased viability of tumor cells derived from a patient-derived xenograft (PDX) model of MYC-driven medulloblastoma, and increased survival of MYC-driven PDX models compared to controls (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3677,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibited tumor growth in MYC-over expressing prostate cancer mouse allograft models (PMID: 25505253).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10157,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of VE-821 and RVX2135 resulted in decreased cell viability and increased levels of PARP cleavage in Myc-driven lymphoma mouse cells in culture (PMID: 26804177).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5419,
                "therapyName": "RVX2135 + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8152,
                    "pubMedId": 26804177,
                    "title": "BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of Myc-overexpressing Burkitt lymphoma cell lines in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Givinostat (ITF2357) decreased viability of tumor cells derived from a MYC-driven medulloblastoma patient-derived xenograft (PDX) model in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 2657,
                "therapyName": "Givinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15075,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-626510 inhibited proliferation and Myc expression, induced apoptosis in uterine corpus serous adenocarcinoma (uterine serous carcinoma) cell lines overexpressing Myc in culture, and suppressed tumor growth in cell line xenograft animal models (PMID: 29941483).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 7414,
                "therapyName": "GS-626510",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12623,
                    "pubMedId": 29941483,
                    "title": "Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29941483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of breast cancer cells with increased MYC activity in culture and inhibited tumor growth in xenograft models (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of lymphocytes over expressing Myc in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5841,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hexamethylene bisacetamide treatment resulted in cell death in Myc over expressing B-cell lymphoma cell lines in culture, and tumor suppression and prolonged survival in xenograft models (PMID: 26941288).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3954,
                "therapyName": "hexamethylene bisacetamide",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5180,
                    "pubMedId": 26941288,
                    "title": "Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26941288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells over expressing MYC demonstrated decreased cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9327,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced cell death in prostate cancer cells derived from MYC-driven transgenic animal models in culture, and inhibited tumor growth in both transgenic and patient-derived xenograft animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of lymphocytes over expressing Myc in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10158,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of RVX2135 and AZ20 resulted in reduced levels of lymphoma cells and improved survival of Myc-driven lymphoma mouse models (PMID: 26804177).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5420,
                "therapyName": "AZ20 + RVX2135",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8152,
                    "pubMedId": 26804177,
                    "title": "BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung carcinoma xenograft models over expressing MYC demonstrated sensitivity to treatment with Barasertib (AZD1152), resulting in tumor growth inhibition (PMID: 27496133).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6752,
                    "pubMedId": 27496133,
                    "title": "Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dacinostat (LAQ824) decreased viability of tumor cells derived from a MYC-driven medulloblastoma patient-derived xenograft (PDX) model in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5034,
                "therapyName": "Dacinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10156,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of VE-821 and JQ1 resulted in a synergistic effect, inhibiting cell growth of Myc-driven lymphoma mouse cells in culture (PMID: 26804177).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5417,
                "therapyName": "JQ1 + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8152,
                    "pubMedId": 26804177,
                    "title": "BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10482,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC-driven mouse lymphoma cells were resistant to induction of apoptosis by LCL161 in culture, and LCL161 accelerated disease progression and increased susceptibility to septic shock in MYC-driven lymphoma mouse models (PMID: 27043662).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3641,
                "therapyName": "LCL161",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8535,
                    "pubMedId": 27043662,
                    "title": "The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27043662"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3627,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 inhibited tumor growth in prostate cancer cell line xenograft models with MYC over expression (PMID: 24293458).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 826,
                    "pubMedId": 24293458,
                    "title": "Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24293458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells over expressing MYC demonstrated decreased cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1095,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 inhibited growth of myeloma cells with MYC over expression in both culture and xenograft models (PMID: 24335499).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 827,
                    "pubMedId": 24335499,
                    "title": "Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24335499"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6863,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation and induced apoptosis in a medulloblastoma model cell line over expressing MYC in culture (PMID: 27012813).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5910,
                    "pubMedId": 27012813,
                    "title": "DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9901,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Farydak (panobinostat) and Buparlisib (BKM120) improved survival of a MYC-driven medulloblastoma patient-derived xenograft (PDX) model compared to either agent alone, and acted synergistically to decrease viability of tumor cells derived from a MYC-driven medulloblastoma PDX model, in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5289,
                "therapyName": "Buparlisib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9307,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 treatment resulted in cell cycle arrest in prostate cancer cells derived from MYC-driven transgenic animal models in culture, inhibited tumor growth, decreased the number of invasive lesions in animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9904,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 decreased viability of tumor cells derived from a MYC-driven medulloblastoma patient-derived xenograft (PDX) model in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9328,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 treatment resulted in cell cycle arrest in prostate cancer cells derived from MYC-driven transgenic animal model in culture, but did not affect the number of invasive lesions in animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Beleodaq (belinostat) decreased viability of tumor cells derived from a MYC-driven medulloblastoma patient-derived xenograft (PDX) model in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 1078,
                "therapyName": "Belinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15074,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-5829 inhibited proliferation of uterine corpus serous adenocarcinoma (uterine serous carcinoma) cell lines overexpressing Myc in culture, reduced Myc expression and suppressed tumor growth in cell line xenograft animal models (PMID: 29941483).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5276,
                "therapyName": "GS-5829",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12623,
                    "pubMedId": 29941483,
                    "title": "Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29941483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of Myc-overexpressing leukemia cell lines in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3676,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment decreased proliferation, increased apoptosis, and inhibited growth of tumor grafts derived from mouse primary prostate epithelial cells over-expressing Myc and Pim1 (PMID: 25505253).",
            "molecularProfile": {
                "id": 14616,
                "profileName": "MYC over exp PIM1 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4442,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mycro3 inhibited tumor growth in transgenic mouse models of Kras G12D-expressing pancreatic adenocarcinoma with Myc overexpression (PMID: 25306215).",
            "molecularProfile": {
                "id": 18158,
                "profileName": "KRAS G12D MYC over exp"
            },
            "therapy": {
                "id": 3507,
                "therapyName": "Mycro3",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4548,
                    "pubMedId": 25306215,
                    "title": "Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25306215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of a C3 medulloblastoma model cell line over expressing constitutively active AKT1, MYC, hTERT, and dominant negative TP53 in culture (PMID: 27012813).",
            "molecularProfile": {
                "id": 23901,
                "profileName": "AKT1 act mut MYC over exp TERT over exp TP53 inact mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5910,
                    "pubMedId": 27012813,
                    "title": "DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012813"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 inhibited growth of multiple myeloma cell lines with MYC amplification and over expression in culture (PMID: 26087190).",
            "molecularProfile": {
                "id": 25920,
                "profileName": "MYC amp MYC over exp"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6444,
                    "pubMedId": 26087190,
                    "title": "MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26087190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8173,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 resulted in decreased expression of BCL2 and BCL2L1 in murine transgenic lymphoma cells over expressing MYC, subsequently leading to increased expression of BCL2L11 (Bim) and apoptotic activity in culture (PMID: 27406984).",
            "molecularProfile": {
                "id": 26187,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8182,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, murine transgenic lymphoma cells over expressing MYC in culture demonstrated resistance to treatment with JQ1 due to a BCL2L11 (Bim)-null background (PMID: 27406984).",
            "molecularProfile": {
                "id": 26191,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transgenic lymphoma mouse model, over expressing MYC and BCL2, treated with JQ1 resulted in a decreased response as indicated by reduced survival (PMID: 27406984).",
            "molecularProfile": {
                "id": 26192,
                "profileName": "BCL2 over exp MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8196,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transgenic murine MYC over expressing lymphoma cells harboring NRAS Q61K demonstrated over expression of BCL2, which resulted in resistance to treatment with JQ1 in culture (PMID: 27406984).",
            "molecularProfile": {
                "id": 26193,
                "profileName": "BCL2 over exp MYC over exp NRAS Q61K"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8582,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC demonstrated resistance to Pictilisib (GDC-0941) in culture, and Pictilisib (GDC-0941) had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in increased tumor cell death and tumor shrinkage in mouse breast cancer cell line allograft models expressing PIK3CA H1047R and over expressing MYC and demonstrated increased efficacy over either agent alone (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 4774,
                "therapyName": "MS417 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8590,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with MS417 did not inhibit growth of a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC in culture, and had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 reduced Myc levels, but did not inhibit growth of a mouse breast cancer cell line expressing PIK3CA H1047R and over expressing MYC in culture (PMID: 26058079).",
            "molecularProfile": {
                "id": 26370,
                "profileName": "MYC over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in increased tumor cell death and tumor shrinkage in mouse breast cancer cell line allograft models with PTEN deletion and MYC over expression, and demonstrated increased efficacy over either agent alone (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 4774,
                "therapyName": "MS417 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8580,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer cell line with over expression of MYC and PTEN deletion demonstrated resistance to Pictilisib (GDC-0941) in culture, and Pictilisib (GDC-0941) had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 reduced Myc levels, but did not inhibit growth of a mouse breast cancer cell line with PTEN deletion and over expression of MYC in culture (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with MS417 did not inhibit growth of a mouse breast cancer cell line with PTEN deletion and over expression of MYC in culture, and had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced inhibition of anchorage-independent growth compared to single agent in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth, but did not induce cell death in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited anchorage-independent growth in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Givinostat (ITF2357) decreased viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and a dominant negative form of TP53 in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 2657,
                "therapyName": "Givinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dacinostat (LAQ824) decreased viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and a dominant negative form of TP53 in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 5034,
                "therapyName": "Dacinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 decreased viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and a dominant negative form of TP53 in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Beleodaq (belinostat) decreased viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and a dominant negative form of TP53 in culture (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 1078,
                "therapyName": "Belinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited anchorage-independent growth in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9896,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) and Buparlisib (BKM120) in combination worked synergistically to reduce viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and dominant negative TP53 in culture, and inhibited tumor growth and increased survival in mice with increased efficacy over either agent alone (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 5289,
                "therapyName": "Buparlisib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9892,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) treatment increased FOXO1 expression and decreased viability of tumor cells derived from a mouse model of G3 medulloblastoma over expressing MYC and a dominant negative form of TP53 in culture, and resulted in an initial reduction in tumor growth in mice (PMID: 26977882).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7750,
                    "pubMedId": 26977882,
                    "title": "HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced inhibition of anchorage-independent growth compared to single agent in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth, but did not induce cell death in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced cell cycle arrest compared to single agent in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth and induced cell death in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9323,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 induced cell cycle arrest in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4715,
            "profileName": "MYC over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 3444,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "MYC over exp"
                },
                {
                    "id": 7762,
                    "name": "c-MYC Inhibitor",
                    "profileName": "MYC over exp"
                }
            ]
        },
        {
            "id": 14616,
            "profileName": "MYC over exp PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18158,
            "profileName": "KRAS G12D MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23901,
            "profileName": "AKT1 act mut MYC over exp TERT over exp TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25920,
            "profileName": "MYC amp MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26187,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26191,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26192,
            "profileName": "BCL2 over exp MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26193,
            "profileName": "BCL2 over exp MYC over exp NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26370,
            "profileName": "MYC over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26371,
            "profileName": "MYC over exp PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26815,
            "profileName": "MYC over exp TP53 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26816,
            "profileName": "MYC over exp TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26817,
            "profileName": "MYC over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}